Groundbreaking Results: Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111).
Positive Topline Results For Autoimmune Disorders Reported By This Major Biotech Company
Positive Topline Results For Autoimmune…
Positive Topline Results For Autoimmune Disorders Reported By This Major Biotech Company
Groundbreaking Results: Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111).